Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering

@article{Yu2017ImprovingAC,
  title={Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering},
  author={Xiaojie Yu and Michaela Marshall and Mark S. Cragg and Max Crispin},
  journal={BioDrugs},
  year={2017},
  volume={31},
  pages={151-166}
}
Antibody-based therapeutics has emerged as a major tool in cancer treatment. Guided by the superb specificity of the antibody variable domain, it allows the precise targeting of tumour markers. Recently, eliciting cellular effector functions, mediated by the Fc domain, has gained traction as a means by which to generate more potent antibody therapeutics. Extensive mutagenesis studies of the Fc protein backbone has enabled the generation of Fc variants that more optimally engage the Fc… 
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
TLDR
The underpinning structure-function relationships and how the Fc has been engineered to produce an increasing number of antibodies that are appearing in the clinic with augmented abilities to treat cancer are revealed.
Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
TLDR
The advances in the understanding of Fc glycobiology and development of novel glycoengineering technologies have facilitated the generation of therapeutic mAbs with homogenous glycoforms and improved therapeutic efficacy.
Boosting therapeutic potency of antibodies by taming Fc domain functions
TLDR
It is reported that monoclonal antibodies can be engineered to activate effective immune cell types to treat a particular disease, and engineering can also increase mAbs’ persistence in the blood, enabling less frequent administration.
In Vivo Glycan Engineering via the Mannosidase I Inhibitor (Kifunensine) Improves Efficacy of Rituximab Manufactured in Nicotiana benthamiana Plants
TLDR
The mannosidase I inhibitor kifunensine was applied to the Nicotiana benthamiana transient expression platform to produce an afucosylated anti-CD20 antibody and revealed a 14-fold increase in ADCC activity targeting the lymphoma cell line Wil2-S when compared with rituximab produced in the absence of kif unensine.
Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer
TLDR
IgG subclasses for cancer therapeutics are reviewed, including IgG1, IgG2, 3, and 4, recent findings on Fc receptor functions, and future directions of reprogramming the constant region of IgG to maximize the efficacy of antibody drug molecules in cancer patients are reviewed.
Assessment of the role of afucosylated glycoforms on the in vitro antibody-dependent phagocytosis activity of an antibody to Aβ aggregates
TLDR
These experiments suggest that afucosylated N-glycans are not critical for the in vitro phagocytic activity of a recombinant antibody whose target is aggregated Aβ and uses Fc effector function as part of its MOA.
1 In vivo Glycan Engineering via the Mannosidase I 2 Inhibitor ( Kifunensine ) Improves Efficacy of 3 Rituximab Manufactured in Nicotiana benthamiana 4 Plants 5
TLDR
This work applied the mannosidase 20 I inhibitor kifunensine to the Nicotiana benthamiana transient expression platform to produce an afucosylated anti-CD20 antibody (rituximab), which revealed a 14-fold increase in ADCC activity targeting the lymphoma cell line Wil2-S when compared with rituximAB produced in the absence of kif unensine.
Glycosylation of IgG-Fc: a molecular perspective
TLDR
The combination of X-ray crystallography with nuclear magnetic resonance, molecular dynamics simulations and biophysical approaches based on thermodynamic principles, has emerged as a powerful combination that is deepened the authors' understanding of this unique system with critical implications for human well-being.
Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
TLDR
The genetic engineering approaches that have allowed isotype switching and Fc modifications to modulate effector functions and bioavailability (half-life), which together with the technologies for engineering the Fv fragment have been pivotal in generating more efficacious and better tolerated therapeutic antibodies to treat cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 189 REFERENCES
Modulating IgG effector function by Fc glycan engineering
TLDR
It is found that core fucosylation exerted a significant adverse effect on FcγRIIIA binding, in vitro ADCC, and in vivo IgG-mediated cellular depletion, regardless of sialylation status.
Polymeric human Fc-fusion proteins with modified effector functions
TLDR
Overall, these findings establish an effective IgG Fc-fusion based polymeric platform with which the therapeutic and vaccination applications of Fc -fusion immune-complexes can now be explored.
Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases.
  • P. Qasba
  • Biology, Chemistry
    Bioconjugate chemistry
  • 2015
TLDR
The mutant or wild-type glycosyltransferases transfer sugars with a chemical handle to the glycan molecule of IgG1, making the site-specific linking of cargo molecules possible via the chemical handle, and thus making the process an invaluable technique for the production of homogeneous ADCs.
Site-specific antibody-drug conjugation through glycoengineering.
TLDR
The findings suggest that enzymatic remodeling combined with oxime ligation of the native glycans of antibodies offers an attractive approach to generate ADCs with well-defined product profiles.
Glycoengineering in cancer therapeutics: a review with fucose-depleted trastuzumab as the model
TLDR
Fucose-depleted trastuzumab is used as a model to show the advantages of this new class of anticancer agents and it is predicted that these advantages will translate clinically into improved therapeutics for many patients including those with HER2-overexpressing neoplasms.
Chemoenzymatic glycoengineering of intact IgG antibodies for gain of functions.
TLDR
The glycoengineering approach described here provides a general platform to modulate the effector functions of IgG antibodies, enabling the optimization of therapeutic efficacy and gain of new functions of monoclonal antibodies and IVIG.
Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
TLDR
The crystal structure shows that one of the two N‐glycans of sFcγRIIIa mediates the interaction with nonfucosylated Fc, thereby stabilizing the complex, and offers a structural basis for improvement in ADCC of therapeutic antibodies by defucOSylation.
Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity
TLDR
A controlled enzymatic, scalable process to produce a tetra-Fc–sialylated (s4-IVIg) IVIg drug candidate and its qualification across a wide panel of analytic assays, including physicochemical, pharmacokinetic, biodistribution, and in vivo animal models of inflammation is described.
Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped during Glycan Biosynthesis
TLDR
This work manipulates the mammalian glycan-processing pathway to trap IgG1 Fc at sequential stages of maturation, and shows that the Fc is structurally stabilized following the transition of glycans from their hybrid- to complex-type state.
...
1
2
3
4
5
...